Aktuellt
SENASTE
Redeye provides its initial take on Scandion Oncology communicating phase IIa CORIST part 3 top-line data. As expected, the trial established an optimal dosing regime and maximum tolerated dose. Further, efficacy readouts, e.g., mPFS of c4.6 months and CBR of c76% after eight weeks, seem promising versus cited historical controls and CORIST part 2. However, we note that the trial's lack of a control group makes efficacy assessments indicative rather than conclusive. Overall, we judge the readout bodes well for SCO-101’s continued clinical development in mCRC. We believe the readout and a recent increase in the company’s share price should facilitate financing of further clinical development. Moreover, we will likely increase our valuation on the back of the readout. We will await the company’s presentation on 05 February before making final adjustments to our estimates and valuation.
LÄS MER
